Show simple item record

dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorBeer, M.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorPantelakos, P.en
dc.contributor.authorTsavaris, N.en
dc.contributor.authorKarpasitis, N.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorFountzilas, Georgeen
dc.creatorPavlidis, Nicholasen
dc.creatorBeer, M.en
dc.creatorMakrantonakis, P.en
dc.creatorAravantinos, Gerasimosen
dc.creatorPantelakos, P.en
dc.creatorTsavaris, N.en
dc.creatorKarpasitis, N.en
dc.creatorKosmidis, Paraskevas A.en
dc.date.accessioned2018-06-22T09:53:15Z
dc.date.available2018-06-22T09:53:15Z
dc.date.issued1993
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41740
dc.description.abstractFifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10% received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. of the 41 patients treated during 4 weeks or longer, 38 experienced weight gain. Monthly subjective evaluation of six parameters using a linear analog self-assessment (LASA) form showed a significant improvement in the patient's rating of appetite, mood, nausea and vomiting, and quality of life; the tumor was progressive in 21, stable in 11 and it regressed in only 9 of these patients. No toxicity was observed; one case of death due to a congestive heart failure remains unexplained. MA at the dose used is a powerful appetite stimulant; it contributes to weight increase and might improve the subjective appreciation of quality of life. MA at lower doses should be compared in a prospective trial to the dose used in this study. ©1993 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.en
dc.language.isoengen
dc.sourceActa Oncologicaen
dc.subjectArticleen
dc.subjectCanceren
dc.subjectHumanen
dc.subjectNeoplasmsen
dc.subject80 and overen
dc.subjectAgeden
dc.subjectAdulten
dc.subjectAgeden
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectPriority journalen
dc.subjectAnorexiaen
dc.subjectMaleen
dc.subjectQuality of lifeen
dc.subjectWeight reductionen
dc.subjectPilot projectsen
dc.subjectOral drug administrationen
dc.subjectMiddle ageen
dc.subjectWeight lossen
dc.subjectMegestrol acetateen
dc.subjectNon-u.s. gov'ten
dc.subjectSupporten
dc.subjectMegestrolen
dc.titleMegestrol acetate in cancer patients with anorexia and weight loss a hellenic co-operative oncology group (heCOG) studyen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3109/02841869309083883
dc.description.volume32
dc.description.issue1
dc.description.startingpage37
dc.description.endingpage41
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidAravantinos, Gerasimos [0000-0002-2106-1713]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-2106-1713


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record